The Yin and Yang of the Opioid Growth Regulatory System: Focus on Diabetes—The Lorenz E. Zimmerman Tribute Lecture

por Sassani, Joseph W., Mc Laughlin, Patricia J., Zagon, Ian S.
Publicado 2016

Naltrexone as a Novel Therapeutic for Diabetic Corneal Complications

por McLaughlin, Patricia J., Sassani, Joseph W., Zagon, Ian S.
Publicado 2020

Sex Differences in Diabetic Ocular Surface Complications and Dysregulation of the OGF-OGFr Pathway

por Zagon, Ian S., Sassani, Joseph W., McLaughlin, Patricia J.
Publicado 2022

Elevated Opioid Growth Factor Alters the Limbus in Type 1 Diabetic Rats

por McLaughlin, Patricia J., Sassani, Joseph W., Diaz, David, Zagon, Ian S.
Publicado 2023

The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer

por Cheng, Fan, McLaughlin, Patricia J, Verderame, Michael F, Zagon, Ian S
Publicado 2008

Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis

por Ludwig, Michael D, Turel, Anthony P, Zagon, Ian S, McLaughlin, Patricia J
Publicado 2016

Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes

por McLaughlin, Patricia J., Sassani, Joseph W., Titunick, Michelle B., Zagon, Ian S.
Publicado 2019

Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis

por McLaughlin, Patricia J, McHugh, Daniel P, Magister, Marcus J, Zagon, Ian S
Publicado 2015

Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis

por McLaughlin, Patricia J, Zagon, Ian S, Park, Sunny S, Conway, Andrea, Donahue, Renee N, Goldenberg, David
Publicado 2009

Low-dose naltrexone reduced anxiety in persons with multiple sclerosis during the COVID-19 pandemic

por McLaughlin, Patricia J., Odom, Laura B., Arnett, Peter A., Orehek, Shannon, Thomas, Gary A., Zagon, Ian S.
Publicado 2022